Type 2 diabetes mellitus metabolic control correlates with the phenotype of human monocytes and monocyte-derived macrophages.
M A Valtierra-Alvarado, J E Castañeda Delgado, S I Ramírez-Talavera...
https://pubmed.ncbi.nlm.nih.gov/32843282/Actively Recruiting
Led by New Valley University · Updated on 2026-07-30
250
Participants Needed
1
Research Sites
26 weeks
Total Duration
Type 2 diabetes mellitus T2DM is a widespread chronic condition linked to insulin resistance and reduced insulin secretion, affecting millions worldwide. It can lead to serious complications such as kidney disease, nerve damage, and heart problems. Researchers are investigating the relationship between red cell distribution width RDW, a measure of variation in red blood cell size, and blood sugar control measured by HbA1C in people with T2DM, as RDW may reflect disease activity or complications. This observational study compares people with uncontrolled T2DM and healthy individuals. Blood tests including RDW, HbA1C, and lipid profiles will be taken at the start for both groups. For participants with T2DM, these tests will be repeated after 3 and 6 months to assess changes following glycemic control. The study aims to understand if RDW correlates with blood sugar levels and other health complications related to diabetes. Participants will provide blood samples at recruitment and follow-up visits at 3 and 6 months for the diabetes group. Researchers will measure how RDW and HbA1C levels relate over time and whether RDW changes associate with other illnesses or complications. The study will monitor participants for up to 6 months, tracking these markers to better understand their potential role in diabetes management.
CONDITIONS
Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control
A
Asmaa N Hussein, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
New Valley University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants provide blood samples for RDW, HbA1C, and lipid profile tests at the start. Those with type 2 diabetes have additional blood tests at 3 and 6 months to monitor changes after glycemic control.
3 visits (at enrollment, 3 months, and 6 months)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
M A Valtierra-Alvarado, J E Castañeda Delgado, S I Ramírez-Talavera...
https://pubmed.ncbi.nlm.nih.gov/32843282/Abdul Rabb Bhutto, Amanullah Abbasi, Ali Hassan Abro
https://pubmed.ncbi.nlm.nih.gov/31687307/Theng Choon Ooi, Arimi Fitri Mat Ludin, Seng Cheong Loke...
https://pubmed.ncbi.nlm.nih.gov/34409130/Eun-Hee Nah, Seon Cho, Hyeran Park...
https://pubmed.ncbi.nlm.nih.gov/35561266/Mesay Arkew, Tilahun Yemane, Yordanos Mengistu...
https://pubmed.ncbi.nlm.nih.gov/34125859/New Valley University
Lead Sponsor